Generate Biomedicines, Inc. (GENB) Stock Statistics & Valuation Metrics

Generate Biomedicines, Inc. has a market cap or net worth of $2.20B. The enterprise value is $1.77K.

Generate Biomedicines, Inc. has 128,352,430 shares outstanding. The number of shares has decreased by -2.65% in one year.

Generate Biomedicines, Inc.’s return on equity (ROE) is 0.33 and return on invested capital (ROIC) is -89.38%.

The current PE Ratio of Generate Biomedicines, Inc. is ―. Generate Biomedicines, Inc.’s PEG ratio is -0.01.

In the last 12 months, Generate Biomedicines, Inc. had revenue of 31.89M and earned -203.15M in profits. Earnings per share was -4.98.

In the last 12 months, operating cash flow was -138.33M and capital expenditures -4.71M, giving a free cash flow of -143.05M billion.

Generate Biomedicines, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―

Generate Biomedicines, Inc. upcoming earnings date is Aug 6, 2026, Before Open (Confirmed).

Generate Biomedicines, Inc. as a current ratio of 2.85, with Debt / Equity ratio of 13.73%

In the past 12 months, Generate Biomedicines, Inc. has paid 163.00K in taxes.

Generate Biomedicines, Inc. EV to EBITDA ratio is -2.78, with an EV/FCF ratio of -2.84.

Generate Biomedicines, Inc. has $457.42M in cash and marketable securities with $62.63M in debt, giving a net cash position of $394.79M billion.

Gross margin is 75.82%, with operating margin of -737.04%, and net profit margin of -636.99%.

The average price target for Generate Biomedicines, Inc. is $26.50, which is 11.43% higher than the current price. The consensus rating is Strong Buy